Acrivon Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
ACRV$1.58-1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| June 30,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $46,006 | $36,015 |
| Short-term investments | 134,531 | 91,443 |
| Prepaid expenses and other current assets | 1,821 | 2,234 |
| Total current assets | 182,358 | 129,692 |
| Property and equipment, net | 3,467 | 3,479 |
| Operating lease right-of-use assets | 3,976 | 4,429 |
| Long-term investments | 39,895 | — |
| Restricted cash | 421 | 414 |
| Deferred offering costs | 468 | 251 |
| Total assets | $230,585 | $138,265 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,261 | $5,048 |
| Accrued expenses and other current liabilities | 9,045 | 7,378 |
| Operating lease liabilities, current | 978 | 877 |
| Total current liabilities | 11,284 | 13,303 |
| Operating lease liabilities, long-term | 3,243 | 3,767 |
| Total liabilities | 14,527 | 17,070 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023; no shares issued and outstanding as of June 30, 2024 and December 31, 2023. | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 30,966,255 and 22,522,644 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. | 31 | 23 |
| Additional paid-in capital | 367,750 | 237,675 |
| Accumulated other comprehensive loss | (19) | (83) |
| Accumulated deficit | (151,704) | (116,420) |
| Total stockholders’ equity | 216,058 | 121,195 |
| Total liabilities and stockholders’ equity | $230,585 | $138,265 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.